New immune cell therapy aims to tame deadly transplant complication
NCT ID NCT07576699
First seen May 08, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-phase trial tests CK0802, a therapy made from special immune cells called Tregs, for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant where donor cells attack the patient's body. The study will check if CK0802 is safe and can improve symptoms in about 12 participants aged 12 and older.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEROID REFRACTORY GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.